MX2022002478A - Proteinas de union a cr2 y su uso en tratamientos medicos. - Google Patents

Proteinas de union a cr2 y su uso en tratamientos medicos.

Info

Publication number
MX2022002478A
MX2022002478A MX2022002478A MX2022002478A MX2022002478A MX 2022002478 A MX2022002478 A MX 2022002478A MX 2022002478 A MX2022002478 A MX 2022002478A MX 2022002478 A MX2022002478 A MX 2022002478A MX 2022002478 A MX2022002478 A MX 2022002478A
Authority
MX
Mexico
Prior art keywords
binding proteins
medical therapy
ebv
epstein
autoimmune
Prior art date
Application number
MX2022002478A
Other languages
English (en)
Spanish (es)
Inventor
James Matthew Bailey
Gerben Bouma
Michael Neil Burden
Caroline J Dimech
David Dixon
Santos Cruz De Mantos Gabriela Dos
Christian Ellson
Laura J Hook
Semra Kitchen
Eleonora Lekova
Emilie Madura
Kiran Nistala
Jian Zhang
Original Assignee
Glaxosmithkline Ip Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip Dev Ltd filed Critical Glaxosmithkline Ip Dev Ltd
Publication of MX2022002478A publication Critical patent/MX2022002478A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2022002478A 2019-08-30 2020-08-28 Proteinas de union a cr2 y su uso en tratamientos medicos. MX2022002478A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1912437.9A GB201912437D0 (en) 2019-08-30 2019-08-30 CR2 Binding Proteins and their use in Medical Therapy
PCT/EP2020/074049 WO2021038023A1 (en) 2019-08-30 2020-08-28 Cr2 binding proteins and their use in medical therapy

Publications (1)

Publication Number Publication Date
MX2022002478A true MX2022002478A (es) 2022-03-22

Family

ID=68207176

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022002478A MX2022002478A (es) 2019-08-30 2020-08-28 Proteinas de union a cr2 y su uso en tratamientos medicos.

Country Status (14)

Country Link
US (1) US20230032643A1 (enExample)
EP (1) EP4021938A1 (enExample)
JP (1) JP7603061B2 (enExample)
KR (1) KR20220053000A (enExample)
CN (1) CN114375305A (enExample)
AR (1) AR119865A1 (enExample)
AU (1) AU2020338807A1 (enExample)
BR (1) BR112022003623A2 (enExample)
CA (1) CA3151687A1 (enExample)
GB (1) GB201912437D0 (enExample)
IL (1) IL290649A (enExample)
MX (1) MX2022002478A (enExample)
TW (1) TWI851801B (enExample)
WO (1) WO2021038023A1 (enExample)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
EP1001021B1 (en) * 1998-09-25 2003-08-27 Wolfgang Prodinger Monoclonal antibody to human CD21, and its uses
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
US20050089932A1 (en) 2001-04-26 2005-04-28 Avidia Research Institute Novel proteins with targeted binding
US20050053973A1 (en) 2001-04-26 2005-03-10 Avidia Research Institute Novel proteins with targeted binding
JP2004529945A (ja) * 2001-05-17 2004-09-30 ラ ホヤ ファーマシューティカル カンパニー Ｃｄ２１を阻害する薬剤を使用して抗体媒介性病理を処置する方法
AU2003298650B2 (en) * 2002-11-15 2010-03-11 Musc Foundation For Research Development Complement receptor 2 targeted complement modulators
US20050164301A1 (en) 2003-10-24 2005-07-28 Avidia Research Institute LDL receptor class A and EGF domain monomers and multimers
US8961967B2 (en) 2009-11-30 2015-02-24 Janssen Biotech, Inc. Antibody Fc mutants with ablated effector functions
BR112012029067A2 (pt) * 2010-05-14 2019-09-24 Univ Colorado Regents grupos-alvo de receptor do complemento 2 (cr2) melhorados.
WO2016187216A1 (en) * 2015-05-18 2016-11-24 Bluebird Bio, Inc. Anti-ror1 chimeric antigen receptors
WO2017189281A1 (en) * 2016-04-27 2017-11-02 The Regents Of The University Of Michigan C3d cellular and acellular vaccines for the prevention and treatment of cancer

Also Published As

Publication number Publication date
TW202126687A (zh) 2021-07-16
IL290649A (en) 2022-04-01
AU2020338807A1 (en) 2022-03-10
JP7603061B2 (ja) 2024-12-19
AU2020338807A8 (en) 2022-06-02
CN114375305A (zh) 2022-04-19
EP4021938A1 (en) 2022-07-06
JP2022545947A (ja) 2022-11-01
TWI851801B (zh) 2024-08-11
AR119865A1 (es) 2022-01-19
US20230032643A1 (en) 2023-02-02
GB201912437D0 (en) 2019-10-16
CA3151687A1 (en) 2021-03-04
KR20220053000A (ko) 2022-04-28
WO2021038023A1 (en) 2021-03-04
BR112022003623A2 (pt) 2022-05-24

Similar Documents

Publication Publication Date Title
MX2025008493A (es) Agentes de union a fibroblastos y uso de estos
PL2643345T3 (pl) Immunogenne peptydy do zastosowania w zapobieganiu i/lub leczeniu chorób zakaźnych, chorób autoimmunologicznych, odpowiedzi immunologicznych na czynniki allogeniczne, chorób alergicznych, nowotworów, odrzuceniu przeszczepów oraz odpowiedzi immunologicznych skierowanych przeciwko wektorom wirusowym stosowanym w terapii genowej lub szczepieniu genowym
ATE503769T1 (de) Antikörper gegen das humane cytomegalie-virus (hcmv)
PH12018501281A1 (en) Human immunodeficiency virus neutralizing antibodies
PH12019500289A1 (en) Vaccines directed against a human enteroviruses
WO2018190719A3 (en) Anti-sirp alpha antibodies
MX2022005253A (es) Anticuerpos neutralizantes de poliomavirus.
GEAP202115055A (en) Anti-cd27 antibodies
PH12021552887A1 (en) Modified viral particles and uses thereof
WO2019106578A3 (en) Polyomavirus neutralizing antibodies
BR112022000710A2 (pt) Vacina viral terapêutica
WO2015054678A3 (en) Human papilloma virus therapeutic vaccine
MX347911B (es) Vacuna contra virus de diarrea viral de bovinos.
MX2022004086A (es) Anticuerpos anti inmunorreceptor de celulas t con dominios de inmunoglobulina y motivo inhibidor basado en tirosina de inmunorreceptor (tigit) y sus usos.
MX2022002478A (es) Proteinas de union a cr2 y su uso en tratamientos medicos.
WO2020053742A3 (en) Anti-hla-hbv peptide antibodies
EA201790771A1 (ru) Фармацевтические композиции длительного действия для лечения гепатита c
EA201790776A1 (ru) Комбинированные композиции длительного действия и способы лечения гепатита с
EA201591095A1 (ru) Белок slurp-1 для применения в лечении глазных болезней
ZA202309368B (en) Lentiviral vector, lentiviral particle for treating hepatitis b and its preparation method and application thereof
EA201991738A1 (ru) Новые соединения (иммунорелины)
WO2020071869A8 (ko) 표적 세포 특이적으로 결합하여 다중 면역기능이 강화된 키메라항원 및 이의용도
MX2019011324A (es) Bloqueo de cxcr4/cxcr7 y tratamiento de enfermedad asociada con el virus del papiloma humano.
WO2015132103A3 (en) Polypeptides derived from enterococcus and their use for vaccination and the generation of therapeutic antibodies
MX2015011064A (es) Vacuna contra el virus de la leucemia bovina.